Prana Biotechnology ADR
WKN: A2AFT0 / ISIN: US7397272045Führend in Alzheimer Forschung! PRANA Biotech.
| eröffnet am: | 15.04.04 20:24 von: | geldschneider |
| neuester Beitrag: | 24.04.21 23:59 von: | Stefaniepyzja |
| Anzahl Beiträge: | 150 | |
| Leser gesamt: | 33798 | |
| davon Heute: | 14 | |
bewertet mit 2 Sternen |
||
|
|
||
MELBOURNE, Australia, May 4, 2005 /PRNewswire-FirstCall via COMTEX/ -- Prana
Biotechnology Limited (Nasdaq: PRAN, ASX: PBT), today announced that its
founding scientist, Professor Ashley Bush of Harvard Medical School, will
present at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference
at the InterContinental Hotel in Paris on Thursday, May 5, 2005, at 12:40 PM
CET.
Professor Bush's presentation will contain a scientific review of the MPAC
(Metal-Protein Attenuating Compounds) theory. A live web cast and replay of the
presentation will be available on the Prana Biotechnology web site:
http://www.pranabio.com.
To arrange a one-on-one meeting with Professor Bush during the conference,
please contact Kathy Price at The Anne McBride Company, tel. 212-983-1702, ext
212, or kprice@annemcbride.com.
The founding scientists', Professors Rudolph Tanzi and Ashley Bush, theories
concerning the interaction between metals and the protein beta-amyloid in the
brain are the basis of Prana's treatments for Alzheimer's and other
neurodegenerative diseases.
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialize research into Alzheimer's
disease and other major age-related degenerative disorders. The company was
incorporated in 1997 and listed on the Australian Stock Exchange in March 2000
and listed on NASDAQ in September 2002. Researchers at prominent international
institutions including the University of Melbourne and Massachusetts General
Hospital, a teaching hospital of Harvard Medical School, discovered Prana's
technology.
For further information, please visit our web site at
http://www.pranabio.com.
Contacts:
Investor Relations Media Relations
Kathy Price Ivette Almeida
T: 212-983-1702 ext. 212 T: 212-983-1702 ext. 209
E: kprice@annemcbride.com E: ivette.almeida@annemcbride.com
SOURCE Prana Biotechnology Limited
CONTACT: Investor Relations
PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN (NEW charting help) {font-weight:bold;color:#ffffff;}.mwExchange {color:#ffffff;}
| |
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
die wissenschaflichen Abhandlung von MPAC (Metal-Protein Attenuating Compounds) theor<.
Die Gründungswissenschaftler: Prof. Rudolph Tanzi und Ashley Bush, stellen die _Theorien
vor, bezüglich der Interaction zwischen Metallen und Protein-Beta-amyloid im Gehirn, die die Basis ist von Prana´s Behandlung für Alzheimer und andere neurodegenerativen Geschehnissen.
Melbourne, Australia – May 13, 2005: Prana Biotechnology Limited (NASDAQ: PRAN, ASX: PBT), today announced that its founding scientist, Professor Ashley Bush of Harvard Medical School and the Mental Health Research Institute of Victoria (Australia), will present at the Banc of America Health Care Conference 2005 at the Four Seasons Hotel in Las Vegas on Thursday, May 19, 2005, at 1:20pm PT (May 19, 6:30pm Melbourne time).
Professor Bush’s presentation will contain a scientific review of the MPAC (Metal-Protein Attenuating Compounds) theory. A live web cast of the presentation will be available on the Prana Biotechnology web site: www.pranabio.com. A web cast replay of the presentation will be archived on the Prana site through June 3, 2005.
To arrange a one-on-one meeting with Professor Bush during the conference, please contact Kathy Price at The Anne McBride Company, tel. 212-983-1702, ext 212, or kprice@annemcbride.com.
The founding scientists’, Professors Rudolph Tanzi and Ashley Bush, theories concerning the interaction between metals and the protein beta-amyloid in the brain are the basis of Prana’s treatments for Alzheimer's and other neurodegenerative diseases.
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialise research into Alzheimer's disease and other major age-related degenerative disorders. The company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including the University of Melbourne and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, discovered Prana’s technology.
For further information, please visit our web site at www.pranabio.com.
###
Contacts:
Investor Relations and media Relations
Rebecca Piercy
Buchan Consulting
T: 03 9866 4722
E: rpiercy@bcg.com.au
--------------------------------------------------
This message contains confidential information and is for the use of intended recipient(s) only. If you have received this e-mail in error you are notified that disclosing, copying, distributing or taking any action in reliance on the contents of this information is strictly prohibited. E-mail transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete. The sender krowe@pranabio.com therefore does not accept liability for any errors or omissions in the contents of this message, which arise as a result of e-mail transmission. If verification is required please request a hard-copy version.
Warning: Although the company has taken reasonable precautions to ensure no viruses are present in this email, the company cannot accept responsibility for any loss or damage arising from the use of this email or attachments.
--------------------------------------------------
Prana Biotechnology to Present at the Needham & Company Fourth Annual Biotechnology Conference
Melbourne, Australia – May 24, 2005 – Prana Biotechnology Limited (NASDAQ: PRAN, ASX: PBT), today announced that its Lead Clinical Advisor, Dr. Craig W. Ritchie of University College London, UK, will present at the Needham & Company Fourth Annual Biotechnology Conference at the New York Palace Hotel in New York City on Thursday, May 26, 2005, at 2:00 p.m. Eastern Time (4:00 am Melbourne time).
Dr. Ritchie’s presentation will contain a scientific review of the MPAC (Metal-Protein Attenuating Compounds) theory. A live web cast of the presentation will be available on the Prana Biotechnology web site: www.pranabio.com. A web cast replay of the presentation will be archived on the Prana site through June 10, 2005.
To arrange a one-on-one meeting with Dr. Ritchie during the conference, please contact Kathy Price at The Anne McBride Company, tel. 212-983-1702, ext 212, or kprice@annemcbride.com.
The founding scientists’, Professors Rudolph Tanzi and Ashley Bush, theories concerning the interaction between metals and the protein beta-amyloid in the brain are the basis of Prana’s treatments for Alzheimer's and other neurodegenerative diseases.
Dr. Ritchie is heavily involved, both clinically and academically, in psychiatric disorders of late life, in particular Alzheimer’s disease, Delirium and Schizophrenia. He leads an international team of investigators developing MPACs for Alzheimer’s disease. He has also worked on several meta-analysis, including one of the current treatments available for Alzheimer’s disease, which was recently published in the American Journal of Geriatric Psychiatry. His interest in conducting and assimilating evidence from clinical trials is based on his clinical background, having worked with elderly patients with dementia for most of his career
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialise research into Alzheimer's disease and other major age-related degenerative disorders. The company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including the University of Melbourne and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, discovered Prana’s technology.
For further information, please visit our web site at www.pranabio.com.
###
Contacts:
Investor and media relations
Rebecca Piercy
Buchan Consulting
T: +61 2 9237 2803
E: rpiercy@bcg.com.au
Celgene, Antisoma,
Imonogen, Abgenix und
vielen Anderen.
Erst ging es auch fulminant hoch, und nun, plus minus null!
Nach den guten News!
| Prana Completes Review of Development Program - Development and Commercialization of MPAC's for the Treatment of Neurodegenerative Diseases Remains Company's Primary Focus and Goal - |
MELBOURNE, Australia, June 16, 2005 /PRNewswire-FirstCall via COMTEX/ -- PranaBiotechnology Limited (Nasdaq: PRAN, ASX: PBT), today announced that it hascompleted the strategic review of the Company's development programs andreaffirmed its commitment to the development of PBT2 for the treatment ofAlzheimer's disease.The Company concluded that: * PBT2 continues as the lead candidate for the potential treatment of Alzheimer's Disease; * based on the Company's evaluation, it is confident that PBT2 will not present the impurity problems that were found in PBT1; and * Prana's primary focus and goal continues to be the development and commercialization of a range of MPAC's (metal-protein attenuating compounds) for the treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.Prana commenced a series of Phase I clinical trials of PBT2 in March, with thedosing of its first subjects at a facility associated with the UtrechtUniversity Hospital in Utrecht, The Netherlands. The Phase I program, comprisingseveral studies, is expected to continue through the balance of 2005 and wellinto 2006."Prana has made considerable progress in developing PBT2 in the past 12 months,"said Geoffrey Kempler, Executive Chairman and CEO. He further noted:* "We have completed a comprehensive battery of in vitro and in vivo tests to characterize the pharmacology and toxicology of the compound prior to the Phase I trial; * PBT2 has successfully passed two (2) in vivo mutagenicity tests; * the Company is successfully advancing scaled up manufacturing in anticipation of GMP production; and * Prana commenced the Phase I clinical trial as scheduled."Alzheimer's Disease is a neurodegenerative disorder estimated to affect over 14million people worldwide. There is no effective cure available to patients.About Prana Biotechnology LimitedPrana Biotechnology was established to commercialize research into Alzheimer'sdisease and other major age-related degenerative disorders. The company wasincorporated in 1997 and listed on the Australian Stock Exchange in March 2000and listed on NASDAQ in September 2002. Researchers at prominent internationalinstitutions including the University of Melbourne, the Massachusetts GeneralHospital (a teaching hospital of Harvard Medical School), and the Mental HealthResearch Institute of Victoria (Australia), discovered Prana's technology.For further information, please visit our web site athttp://www.pranabio.com Contacts: Investor Relations Media Relations Kathy Price Ivette Almeida T: 212-983-1702 ext. 212 T: 212-983-1702 ext. 209 E: kprice@annemcbride.com E: ivette.almeida@annemcbride.comSOURCE Prana Biotechnology LimitedCONTACT: Ivette Almeida, +1-212-983-1702 ext. 209, ivette.almeida@annemcbride.com, Investors: Kathy Price, +1-212-983-1702 ext. 212, kprice@annemcbride.comURL: http://www.prnewswire.com http://www.pranabio.comwww.prnewswire.comCopyright (C) 2005 PR Newswire. All rights reserved.KEYWORD: AustraliaINDUSTRY KEYWORD: BIO HEA MTC |
WASHINGTON, June 20, 2005 /PRNewswire-FirstCall via COMTEX/ -- PranaBiotechnology Limited (Nasdaq: PRAN; ASX: PBT), announced today that itsco-founding scientists, Drs. Ashley Bush, MD PhD of Massachusetts GeneralHospital and the Mental Health Research Institute of Victoria (Australia); andRudolph Tanzi, PhD of Harvard Medical School and Massachusetts General Hospitalare scheduled to co-chair and present at the Alzheimer's AssociationInternational Conference on Prevention of Dementia 2005. Both doctors willreside as co-chairmen at separate sessions for the pre-conference meeting onJune 18 called "Clinical Trials Test the "Amyloid Hypothesis": A tutorial onCurrent Approaches and its Mechanisms. The Conference will be held at theMarriott Wardman Park Hotel, Washington DC.Scientists from around the world will present and discuss the findings ofhundreds of studies showcasing the newest advances and steps toward preventionof Alzheimer's disease and related disorders. At the pre-conference, Dr. Tanziwill co-chair the morning session on 'Brain Amyloid-beta Peptide Oligomers asTherapeutic Targets.' This assembly will discuss the potential of amyloidaccumulation in the brain in Alzheimer's disease as a new drug target. Inaddition, Dr. Tanzi will share his view about the genetic basis for amyloidaccumulation in Alzheimer's disease in a lecture called 'Genetic basis ofCerebral Amyloidosis.'In the afternoon session, Dr. Bush will co-chair a discussion on theanti-amyloid drug development that does not directly target amyloid, but thechemistry that interacts with the amyloid (metals) called, 'Anti-amyloidStrategies with Complex Targets.' Dr. Bush also intends to present a lectureentitled 'Antagonists of Metal-dependent Oxidation and Protein Interactions'that will focus on the interaction between metals and the protein beta-amyloid,which leads to the toxicity and accumulation.These insights are the basis of the development of Prana's library of MPAC's(metal protein attenuating compounds), which target neurodegenerative diseases.PBT2, Prana's lead MPAC drug candidate for the potential treatment ofAlzheimer's disease is currently in Phase 1 clinical development.At the conference, nearly 1,000 clinicians, physicians, researchers and policyadvocates will explore how science and technology intersect to open new doorsfor Alzheimer research and care.About Prana Biotechnology LimitedPrana Biotechnology was established to commercialise research into Alzheimer'sdisease and other major age-related degenerative disorders. The company wasincorporated in 1997 and listed on the Australian Stock Exchange in March 2000.Researchers at prominent international institutions including the University ofMelbourne and Massachusetts General Hospital at Harvard Medical Schooldiscovered Prana's technology.This press release contains "forward looking statements" within the meaning ofthe Private Securities Litigation Reform Act of 1995 regarding the Company'sbusiness strategy and future plans of operation. Forward-looking statementsinvolve known and unknown risks and uncertainties; both general and specific tothe matters discussed in this press release. These and other important factors,including those mentioned in various Securities and Exchange Commission filingsmade by the Company, may cause the Company's actual results and performance todiffer materially from the future results and performance expressed in orimplied by such forward-looking statements. The forward-looking statementscontained in this press release speak only as of the date hereof and the Companyexpressly disclaims any obligation to provide public updates, revisions oramendments to any forward-looking statements made herein to reflect changes inthe Company's expectations or future events.For further information, please visit our web site athttp://www.pranabio.com. Investor Media Kathy Price Ivette Almeida The Anne McBride Company The Anne McBride Company 212-983-1702 ext. 207 212-983-1702 ext. 209SOURCE Prana Biotechnology LimitedCONTACT: Investor: Kathy Price, ext. 207, or Media: Ivette Almeida, ext. 209, both of The Ann McBride Company, +1-212-983-1702, for Prana Biotechnology LimitedURL: http://www.prnewswire.com http://www.pranabio.comwww.prnewswire.comCopyright (C) 2005 PR Newswire. All rights reserved.
<!--StartFragment -->
MELBOURNE, Australia, July 26, 2005 /PRNewswire-FirstCall via COMTEX/ -- PranaBiotechnology Limited (Nasdaq: PRAN, ASX: PBT), today announced that itsfounding scientist, Professor Ashley Bush of Harvard Medical School and theMental Health Research Institute of Victoria (Australia), will present at theBanc of America 2005 Specialty Pharmaceuticals Conference at The Southampton Innin Southampton, NY on Friday, July 29, 2005, at 8:00 a.m. Eastern Time.Professor Bush's presentation will contain a scientific review of the MPAC(Metal-Protein Attenuating Compounds) theory. A live web cast of thepresentation will be available on the Prana Biotechnology web site:http://www.pranabio.com. A web cast replay of the presentation will be archivedon the Prana site through August 12, 2005.To arrange a one-on-one meeting with Professor Bush during the conference,please contact Kathy Price at The Anne McBride Company, tel. 212-983-1702, ext212, or kprice@annemcbride.com.The founding scientists', Professors Rudolph Tanzi and Ashley Bush, theoriesconcerning the interaction between metals and the protein beta- amyloid in thebrain are the basis of Prana's treatments for Alzheimer's and otherneurodegenerative diseases.About Prana Biotechnology LimitedPrana Biotechnology was established to commercialize research into Alzheimer'sdisease and other major age-related degenerative disorders. The company wasincorporated in 1997 and listed on the Australian Stock Exchange in March 2000and listed on NASDAQ in September 2002. Researchers at prominent internationalinstitutions including the University of Melbourne and Massachusetts GeneralHospital, a teaching hospital of Harvard Medical School, discovered Prana'stechnology.For further information, please visit our web site athttp://www.pranabio.com. Contacts: Investor Relations Kathy Price 212-983-1702 ext. 212 kprice@annemcbride.com
gestern der 5- fache Tagesumsatz
<!--StartFragment --> Gestern endlich diel lezten verkauft zu 1, 36 und nun zeiht heute der Kurs an!<!--StartFragment --> Exchange Quote
| Last | Change (%) | Trade Time | Bid (size) | Ask (size) |
| 1.44 |  0.09 (6.67) | 11:34 | 1.40 (1) | 1.46 (63) |
| Latest Ticks | Prev Close | Open | Low | High |
| +==- | 1.35 | 1.38 | 1.33 | 1.45 |
| Day Volume | Avg Day Vol | VWAP | 52 Wk Low | 52 Wk High |
| 26,800 | 12,600 | 1.3972 | 0.98 | 5.05 |
| # of Trades | Last Size | Avg Trade Size | P/E Ratio | Market Cap (mil) |
| 29 | 200 | 924 | 0 | 24 |
| |
 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Heute sochn 30.000 Stück umgesetzt, da versthe einer noch die Börse! Die News oben kann es doch nicht sein??
<!--StartFragment --> Und das nach der Vorgabe in der Heimatbörse??? Da brate mir einer einen Storch! Die News war wohl nach Börsenschluss in Ausstralien rausgekommen?
PBT) PRANA BIOTECHNOLOGY LIMITED
ORDINARY FULLY PAID
| 29 Jul 2005 19:02 |
|
$-0.0100 In Australien habe ich die Nachricht erst gar nicht gefunden, und sie ist heute morgen veröffentlich wroden, wieviel Uhr es in Australien war, weis cih nicht.
Heute ist die wichtige Konferenz und man kann hören und rechts die Wissenschaftliche Studie ansehen!
http://www.veracast.com/webcasts/bas/sp05/id99201247.cfm
Das ist wohl der Grund für den Kursanstieg!
57900 bis jetzt!
<?xml:namespace prefix = v ns = "urn:schemas-microsoft-com:vml" /><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /> | ||
Friday, July 29, 2005 |
| ||||||||
[Click here to open a window to print these slides.] |
|
Erhebliche Umsätze und Interesse seit der Biotechkonferenz s. o.vom 29..7.05.
Es decken sich Fonds ein und es gibt Übernahmegerüchte.
<!--StartFragment -->
| PRAN - Prana Biotechnology Ltd (NASDAQ SC) | 12:35 PM ET, 8/2/2005 |
habe nicht immer zeit
by: Send me a message! tyasdfghjkl 08/08/05 02:25 pm
Msg: 1358 of 1359
Schwab took 30k in two 15k blocks and marked it up and MLCO took 15k in. Someone accumulating it for some reason. Anyone know of any upcoming meetings or presentations of any new safety data?
Posted as a reply to: Msg 1357 by techcoat3
aus dem yahhoo board.
xpfuture
| PRAN - Prana Biotechnology Ltd (NASDAQ SC) | 3:59 PM ET, 8/23/2005 |
War schon wieder draußen und bin bei 1,43 dann wieder rein, Heute, 1,67.
gruß
gs
Melbourne, Australia – November 7, 2005: Prana Biotechnology Limited (NASDAQ: PRAN, ASX: PBT), today announced the successful completion of a Phase I trial with its lead compound, PBT2, under development as a therapy for Alzheimer’s Disease. <?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />
The double blind, placebo-controlled single dose escalation study, conducted at a facility in <?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" />Utrecht, The Netherlands on 55 healthy, male volunteers between the ages of 18 and 50, was designed to evaluate the safety, tolerability and pharmacokinetics of PBT2.
Data from the study showed PBT2 was well tolerated with little difference in the incidence of adverse events between those receiving PBT2 and those receiving the placebo. In addition, the pharmacokinetic analysis demonstrated that the drug exposure increased predictably and in a linear manner, both of which are excellent characteristics for a central nervous system (CNS) drug. Concurrent pre-clinical findings also firmly indicated that PBT2 passes into the brain with more than 20 times greater efficiency than did its predecessor, PBT1.
“The clinical and pre-clinical results to date are compelling,” said Ross Murdoch, Chief Operating Officer. “The trials confirm our laboratory studies showing that PBT2 has great potential for the treatment of Alzheimer’s Disease, which currently affects 4.5 million people in the US and more than 14 million people worldwide.”
Prana scientists discovered a common interaction of metals and proteins leading to oxidative damage to the brain that is characteristic of patients with Alzheimer’s Disease, Parkinson’s Disease and other neurodegenerative disorders. MPAC’s (Metal Protein Attenuating Compounds) target abnormal protein-metal interactions preserving normal metal biochemistry.
“Prana MPAC’s, of which PBT2 is the lead compound, take advantage of novel insights into the role of metals and oxidation as the cause of Alzheimer’s Disease, and may be the first ‘plaque busting’ drugs,” added Geoffrey Kempler, Executive Chairman and CEO. “The early results Prana has observed in the trials of PBT2 are extremely exciting and give hope to the battle against Alzheimer’s Disease”.
Looking Ahead
Prana has nearly completed a multi-dose escalation safety clinical trial of PBT2 in elderly, healthy, male and female volunteers, having completed three out of four stages of dose escalation. The company anticipates completing the final dosing stage in December this year. In addition, the chronic toxicology studies and GMP manufacturing development required for Phase II and Phase III clinical studies are underway concurrently.
Prana already has support for PBT2's efficacy via its original ‘proof of concept’ drug, PBT1. (PBT1 demonstrated benefit for Alzheimer’s Disease patients compared to placebo in a Phase II study.) PBT2 is a related derivative of PBT1, they are both 8-hydroxyquinolines, but was designed specifically for greater safety, efficacy and brain penetration.
“Given the existing pre-clinical and human clinical performance of PBT2 to date, we hold very high expectations for the drug in Phase II trials,” concluded Mr. Kempler.
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialise research into Alzheimer's disease and other major age-related degenerative disorders. The company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including the University of Melbourne and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, discovered Prana’s technology.
For further information, please visit our web site at www.pranabio.com.
###
Contacts:
Investor and media relations
Rebecca Piercy
Buchan Consulting
Ph: +61 3 9866 4722
rpiercy@bcg.com.au
Melbourne, Australia – November 3, 2005: Prana Biotechnology Limited (NASDAQ: PRAN, <?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" />ASX: PBT), today announced that Geoffrey Kempler, Executive Chairman and Chief Executive Officer, will present at the Rodman & Renshaw Techvest Seventh Annual Healthcare Conference at 3:50 p.m. Eastern Time on Tuesday, November 8 (7.50am Melbourne Time on Wednesday, November 9) at The New York Palace Hotel. During the presentation, Mr. Kempler will address the current status of Prana’s development program.<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />
The Company’s audio and slide presentation will be web cast live on November 8. A replay will be available one hour following the presentation and archived on the Company’s web site for 90 days. To access the live and replay presentations, visit the Prana Biotechnology web site, www.pranabio.com.
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. The company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including the University of Melbourne and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, discovered Prana’s technology.
For further information, please visit our web site at www.pranabio.com.
###
Contacts:
Investor Relations Media Relations
Kathy Price Ivette Almeida
The Global Consulting Group The Global Consulting Group
T: 646-284-9430 T: 646-284-9455
E: kprice@hfgcg.com E: ialmeida@hfgcg.com
| PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN |
| Last | Change (%) | After Hours Chg (%)** | Trade Time | Bid | Ask |
| 1.80 | 0.3 (20.00) | 0 (0.00) | 15:59 | 1.50 (25) | 1.85 (19) |
| At Scottrade, we listen to our customers and have improved the trading technology serving them. Our online trading is fast, accurate and easy to use. And, online trades are still just $7. Apply now. |
Exchange Quote
| Last | Change (%) | Trade Time | Bid (size) | Ask (size) |
| 1.80 | 0.30 (20.00) | 15:59 | 1.50 (25) | 1.85 (19) |
| Latest Ticks | Prev Close | Open | Low | High |
| ==-+ | 1.50 | 1.52 | 1.52 | 1.85 |
| Day Volume | Avg Day Vol | VWAP | 52 Wk Low | 52 Wk High |
| 224,781 | 8,600 | 1.7219 | 0.98 | 4.99 |
| # of Trades | Last Size | Avg Trade Size | P/E Ratio | Market Cap (mil) |
| 239 | 1,000 | 941 | 0 | 23 |
4:34:24 PM EST - Tuesday, November 8, 2005- Exchange quote is delayed at least 15 minutes.
<!--StartFragment --> PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN (NEW charting help)
<!--VITALS="app:interactivecharting lic:destination sale:kek web:kjb ops:ccn tech:cdt"-->
| ||||||||||||||||